"SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming neutral endopeptidase and endothelin-converting enzyme inhibition. The combined inhibition of neutral endopeptidase and endothelin-converting enzyme may be useful in heart failure by reducing right and left cardiac filling pressures"@en . . . . "investigational"@en . "SLV 306"@en . . "SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the treatment of essential hypertension and congestive heart failure and it is in the phase II of clinical trails."@en . . . . . . "Investigated for use/treatment in congestive heart failure and hypertension."@en . . . . . . . . . . . . . . . "# Tabrizchi R: SLV-306. Solvay. Curr Opin Investig Drugs. 2003 Mar;4(3):329-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12735234"@en . . . . . . . . .